Family Planning Access Program

Since 2013, JSI has leveraged its over 30 years of leadership in health supply chain management to monitor various family planning (FP) pharmaceutical agreements negotiated by the Bill & Melinda Gates Foundation (the Foundation) with manufacturers. These agreements were enacted under the Family Planning 2020 initiative (FP2020) to reduce the public sector purchase price of three- and five-year contraceptive implants Jadelle® and Nexplanon®, respectively, and Sayana® Press, a subcutaneous (SC) three-month injectable of depot medroxyprogesterone (DMPA), and thereby increase global access to the products and thus contraceptive choice.

Funded by the Foundation, the Family Planning Access Program (FPAP) inclusively encompasses JSI’s work to support and monitor progress towards these agreements. Specifically, this work includes:

• Monitoring global shipment volumes and related supply information for the two contraceptive implants, completed at conclusion of the Implants Access Program in December 2018;

• Monitoring global shipment volumes and related supply information for DMPA-SC, and using this information to update donors on progress under the agreements and support countries in strengthening their FP product supply chains;

• Leading and providing technical support to the Coordinated Supply Planning (CSP) group, a cross-organizational team that strives to prevent family planning (FP) commodity stock imbalances by using shared supply chain data and information to coordinate shipments and the allocation of resources within and among countries;

• Leading data and partner coordination for shipment allocation and prioritization for several products with short-term supply constraints to minimize risk of severe country and program level shortages and stockouts;

• Collecting and reviewing supply plans for countries and programs to evaluate needs against requests, orders, and proactively flag funding gaps;

• Providing technical leadership to the Reproductive Health Supplies Coalition (RHSC) on the development and implementation of the Global Family Planning Visibility and Analytics Network (GFPVAN);

• Developing novel forecasting methods to create rolling, quarterly global product forecasts to share with manufacturers;

• Modeling inventory requirements during implant program growth in 10 countries, the results of which were published Global Health Science and Practice in Q3 2019.